Gilead Sciences, Inc.

- Gilead does not expect sizable M&A (mergers and acquisitions) in the near term. - The company has a strong cash position (about $5 billion) and leverage back to pre-Immunomedics deal levels. - Focus remains on ordinary corporate development and licensing deals rather than meaningful M&A. - Gilead emphasizes disciplined use of capital and intends to continue generating operating cash flow to invest in its pipeline. - No mention of planned new fundraising through debt or equity in the provided transcript. - Current priority is managing existing assets and pipeline investments without sizable new external financing.

- Gilead is focused on expanding its cell therapy capabilities, including plans to double manufacturing capacity and move into new indications and disease areas with next-generation products. - The company is investing in its pipeline, including advancing next-generation CAR-T lymphoma assets with in-house vector and construct creation. - Post-acquisition of CymaBay, Gilead expects to make incremental investments to support the launch of seladelpar and other R&D efforts, managed within existing expense guidance. - Capital allocation remains disciplined with a focus on ordinary corporate ventures and licensing deals. Sizable M&A is not expected in the near term as the company prioritizes internal growth and pipeline execution. - Gilead continues to make modest investments reflected in R&D growth at the higher end of the previous guidance and some increase in SG&A relating to the CymaBay acquisition. - The company maintains flexibility in its balance sheet to support capital allocation priorities, including potential strategic investments.

- Total product sales (excluding Veklury) expected to grow 4-6% in 2024, reaching $25.8 to $26.2 billion. - Base business projected to grow despite HIV Part D Medicare redesign headwinds; overall business growth expected in 2025. - HIV sales expected to be roughly flat year-over-year in 2025 due to Part D impact. - Trodelvy continues strong growth with sales exceeding $1 billion annually, with multiple Phase 3 trials underway for new indications. - Cell therapy sales (Yescarta and Tecartus) growing, with expansion into new indications and regions like Japan. - Seladelpar (from CymaBay acquisition) expected to contribute modestly in 2024 and more meaningfully in 2025 and beyond. - Continued growth anticipated from HIV pipeline innovations including long-acting therapies and new oral regimens. - Focus on disciplined expense management and margin expansion supports sustainable growth.

- For 2024, revenue expectations remain unchanged, with total product sales anticipated between $27.1 to $27.5 billion, excluding Veklury at $1.3 billion. - Non-GAAP diluted EPS guidance for 2024 is updated to $3.45 to $3.85, reflecting a nondeductible $3.9 billion acquired IPR&D charge from the CymaBay acquisition; excluding this, EPS aligns with earlier guidance. - The CymaBay acquisition is expected to be dilutive to EPS in 2024 but break even in 2025, then become significantly accretive thereafter. - HIV sales are expected to be roughly flat year-over-year in 2025 due to Medicare Part D redesign impact; however, total business growth is still anticipated. - The company emphasizes disciplined expense management and expects operating margin improvement over time, driven by top-line growth and cost control. - Detailed 2025 financial guidance will be provided early next year.

The provided pages from the Gilead Sciences Q1 2024 earnings call transcript do not explicitly mention details about the current or expected order book or pending orders. The discussion mainly focuses on: - Sales growth in HIV, oncology, liver disease, and the impact of product launches like seladelpar. - Expectations of product sales growth for 2024. - Pipeline and clinical trial progress, including CAR-T therapies and Trodelvy. - No direct references to order books or pending orders were given in the transcript excerpts available. Therefore, no specific quantitative or qualitative information on current or expected order books or pending orders is disclosed in these pages.